{
    "clinical_study": {
        "@rank": "28368", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Other", 
            "description": "Single Omegaven\u00ae Intervention Arm"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the omega-3 fatty acid emulsion\n      (Omegaven\u00ae), when used in place of the conventional soy-based fat emulsion (Intralipid), is\n      effective in treating parenteral nutrition associated liver disease (PNALD) in children.\n\n      The study hypothesis is that Omegaven\u00ae can be safely provided to children who are dependent\n      on parenteral nutrition and have PNALD, and can reverse or prevent progression of PNALD\n      until the child can take adequate nutrition by mouth."
        }, 
        "brief_title": "Omegaven\u00ae in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Parenteral Nutrition Associated Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children 0-18 years of age\n\n          -  Patients will be PN-dependent and expected to continue PN for at least 30 days\n\n          -  Patients considered eligible for study participation must have PN-associated liver\n             diseases . Other causes of liver disease (i.e., biliary atresia, galactosemia,\n             alpha-1 antitrypsin deficiency) will be excluded. A liver biopsy is not necessary for\n             treatment\n\n          -  Direct bilirubin > 2.0 mg/dl\n\n          -  Signed patient informed consent\n\n          -  Signed patient assent where applicable.\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Other causes of chronic liver disease (cystic fibrosis, biliary atresia, alpha-1\n             antitrypsin deficiency)\n\n          -  Signs of advanced liver disease including cirrhosis on biopsy, varices, ascites\n\n          -  The patient is allergic to eggs/shellfish\n\n          -  The patient has a severe hemorrhagic disorder\n\n          -  The patient is enrolled in any other clinical trial involving an investigational\n             agent (unless approved by the designated physicians on the multidisciplinary team)\n\n          -  The parent or guardian or child unwilling to provide consent or assent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845116", 
            "org_study_id": "Omegaven 04-10-18B"
        }, 
        "intervention": {
            "arm_group_label": "Single Arm", 
            "description": "10% Omegaven\u00ae initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.", 
            "intervention_name": "Omegaven\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "IV Fish Oil Based Lipid Emulsion"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PNALD", 
            "Cholestasis", 
            "Omegaven\u00ae", 
            "Short Bowel Syndrome"
        ], 
        "lastchanged_date": "May 1, 2013", 
        "location": {
            "contact": {
                "email": "ricardo.caicedo@carolinashealthcare.org", 
                "last_name": "Ricardo A. Caicedo, MD", 
                "phone": "704-381-8880"
            }, 
            "facility": {
                "address": {
                    "city": "Charlotte", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "28232-2861"
                }, 
                "name": "Levine Children's Hospital at Carolinas HealthCare System"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Use of a Fish Oil-Based Intravenous Lipid Emulsion (Omegaven\u00ae) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury", 
        "overall_contact": {
            "email": "ricardo.caicedo@carolinashealthcare.org", 
            "last_name": "Ricardo A. Caicedo, MD", 
            "phone": "704-381-8880"
        }, 
        "overall_contact_backup": {
            "email": "michelle.chiu@carolinashealthcare.org", 
            "last_name": "Michelle K. Chiu, MD", 
            "phone": "704-381-4833"
        }, 
        "overall_official": {
            "affiliation": "Levine Children's Hospital at Carolinas HealthCare System", 
            "last_name": "Ricardo A. Caicedo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Normalization or trend toward normalization of direct bilirubin level", 
            "measure": "Efficacy of parenteral administration of fish oil derived fat emulsion (Omegaven\u00ae) to reverse established parenteral nutrition associated liver disease", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "19661785", 
                "citation": "Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, Zhou J, Duggan C, Gura KM. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep;250(3):395-402."
            }, 
            {
                "PMID": "18310188", 
                "citation": "Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP, Arsenault DA, Strijbosch RA, Lopes S, Duggan C, Puder M. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar;121(3):e678-86."
            }, 
            {
                "PMID": "16818533", 
                "citation": "Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR, Puder M. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul;118(1):e197-201."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845116"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Carolinas Healthcare System", 
            "investigator_full_name": "Ricardo Caicedo", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Carolinas Healthcare System", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Carolinas Healthcare System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}